NewAmsterdam Pharma Co. N.V. (NAMS)
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial Transcript
NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial Transcript
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
NewAmsterdam Pharma NASDAQ: NAMS said it plans to conduct an interim analysis of its ongoing PREVAIL cardiovascular outcomes trial (CVOT) for obicetrapib in the fourth quarter of 2026, citing what executives described as encouraging trends in two-year blinded data and a lower-than-anticipated major adverse cardiovascular event (MACE) rate from year one to year two.
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.46.
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy?
NewAmsterdam Pharma Company N.V. (NAMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
NewAmsterdam Pharma Company N.V. (NAMS) Soars 5.9%: Is Further Upside Left in the Stock?
NewAmsterdam Pharma Company N.V. (NAMS) was a big mover last session on higher-than-average trading volume.
NewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference Transcript
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS ) Citi's Biopharma Back to School Conference September 3, 2025 2:30 PM EDT Company Participants Michael Davidson - CEO, President & Executive Board Member Mayur Somaiya - Chief Financial Officer Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoffrey Meacham Managing Director All right.
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.52.
Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 132.5% in NewAmsterdam Pharma Company N.V. (NAMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.45.
